NCT01572493View on ClinicalTrials.gov

Continuous Infusion of rhIL-15 for Adults With Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

April 4, 2012

Primary Completion Date

June 20, 2019

Study Completion Date

July 2, 2019

Conditions
LymphomaCarcinoma
Interventions
BIOLOGICAL

rh IL-15 (10 DAYS)

Continuous infusion of recombinant human Interleukin-15 (rh IL-15) intravenous (IV) for first 10 days of each cycle

BIOLOGICAL

rh IL-15 (5 DAYS)

Continuous infusion of recombinant human Interleukin-15 (rh IL-15) for first 5 days of each cycle

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT01572493 - Continuous Infusion of rhIL-15 for Adults With Advanced Cancer | Biotech Hunter | Biotech Hunter